Advertisement
Screener

OCUGEN, INC. (OCGN) Total Long-Term Debt

2.8 / 5 stars · 68/120 Roast Me

OCUGEN, INC. Total Long-Term Debt

OCUGEN, INC. (OCGN) had Total Long-Term Debt of $1.71 million as of 2021-12-31, per its 10-K filed 2022-02-28.

Discontinued › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified

us-gaap:LongTermDebt · last filed 2022-02-28

  • 2021-12-31: Long-term Debt $1.71M.
  • 2021-09-30: Long-term Debt $1.69M.
  • 2021-06-30: Long-term Debt $1.67M.
  • 2021-03-31: Long-term Debt $2.08M.
Period endLong-term DebtLong-term Debt as first filed
2021-12-31$1.71M
10-K · filed 2022-02-28
2021-09-30$1.69M
10-Q · filed 2021-11-09
2021-06-30$1.67M
10-Q · filed 2021-08-06
2021-03-31$2.08M
10-Q · filed 2021-05-07
2020-12-31$2.06M
10-K · filed 2022-02-28
$2.06M
10-K · filed 2021-03-19
2020-09-30$3.16M
10-Q · filed 2020-11-06
2020-06-30$6.09M
10-Q · filed 2020-08-14
2019-12-31$1.07M
10-K · filed 2021-03-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cabaletta Bio, Inc. (CABA)United States$0.365B-2.81
Artiva Biotherapeutics, Inc. (ARTV)United States$0.367B
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
AGENUS INC (AGEN)United States$0.383B1.41
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
Surrozen, Inc./DE (SRZN)United States$0.395B